Fairmount Funds Management
Latest statistics and disclosures from Fairmount Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AXSM, NUVL, APGE, SYRE, ELVN, and represent 57.16% of Fairmount Funds Management's stock portfolio.
- Added to shares of these 5 stocks: Oruka Therapeutics (+$79M), DAWN (+$43M), VRDN (+$36M), Bicara Therapeutics (+$33M), Zenas Biopharma (+$32M).
- Started 4 new stock positions in DAWN, Oruka Therapeutics, Zenas Biopharma, Bicara Therapeutics.
- Reduced shares in these 5 stocks: PTGX (-$32M), NUVL (-$24M), BCYC (-$21M), TERN (-$5.1M), DNTH.
- Sold out of its positions in PTGX, TERN.
- Fairmount Funds Management was a net buyer of stock by $138M.
- Fairmount Funds Management has $1.2B in assets under management (AUM), dropping by 39.33%.
- Central Index Key (CIK): 0001802528
Tip: Access up to 7 years of quarterly data
Positions held by Fairmount Funds Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 15 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 17.2 | $212M | 2.4M | 89.87 |
|
|
| Nuvalent Inc-a (NUVL) | 14.0 | $173M | -12% | 1.7M | 102.30 |
|
| Apogee Therapeutics (APGE) | 9.8 | $120M | 2.0M | 58.74 |
|
|
| Spyre Therapeutics Com New (SYRE) | 9.6 | $118M | 4.0M | 29.41 |
|
|
| Enliven Therapeutics (ELVN) | 6.6 | $82M | 3.2M | 25.54 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 6.5 | $80M | 3.2M | 24.99 |
|
|
| Oruka Therapeutics | 6.4 | $79M | NEW | 3.2M | 24.51 |
|
| Miragen Therapeutics (VRDN) | 6.4 | $78M | +86% | 3.4M | 22.75 |
|
| Dianthus Therapeutics (DNTH) | 6.0 | $74M | -2% | 2.7M | 27.38 |
|
| Cogent Biosciences (COGT) | 5.5 | $67M | 6.2M | 10.80 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 3.5 | $43M | NEW | 3.1M | 13.93 |
|
| Astria Therapeutics (ATXS) | 3.2 | $39M | 3.6M | 11.01 |
|
|
| Bicara Therapeutics | 2.7 | $33M | NEW | 1.3M | 25.47 |
|
| Zenas Biopharma | 2.6 | $32M | NEW | 1.9M | 16.92 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.2 | $2.8M | -88% | 124k | 22.63 |
|
Past Filings by Fairmount Funds Management
SEC 13F filings are viewable for Fairmount Funds Management going back to 2019
- Fairmount Funds Management 2024 Q3 filed Nov. 14, 2024
- Fairmount Funds Management 2024 Q2 filed Aug. 14, 2024
- Fairmount Funds Management 2024 Q1 filed May 15, 2024
- Fairmount Funds Management 2023 Q4 filed Feb. 14, 2024
- Fairmount Funds Management 2023 Q3 filed Nov. 14, 2023
- Fairmount Funds Management 2023 Q2 filed Aug. 14, 2023
- Fairmount Funds Management 2023 Q1 filed May 15, 2023
- Fairmount Funds Management 2022 Q4 filed Feb. 14, 2023
- Fairmount Funds Management 2022 Q3 filed Nov. 9, 2022
- Fairmount Funds Management 2022 Q2 filed Aug. 15, 2022
- Fairmount Funds Management 2022 Q1 filed May 16, 2022
- Fairmount Funds Management 2021 Q4 filed Feb. 14, 2022
- Fairmount Funds Management 2021 Q3 filed Nov. 15, 2021
- Fairmount Funds Management 2021 Q2 filed Aug. 13, 2021
- Fairmount Funds Management 2021 Q1 filed May 14, 2021
- Fairmount Funds Management 2020 Q4 filed Feb. 12, 2021